Weight-loss frenzy leaves Eli Lilly’s diabetes drug Mounjaro in short supply again
The FDA says there will be ”intermittent backorders” for three of six of the US-based drugmaker’s doses, lasting through July.
By Emma Court, Bloomberg
Some dosages of Eli Lilly & Co.’s Mounjaro are again in shortage, the latest in a line of recurring supply issues caused by patients using the diabetes medication as a weight-loss treatment.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
